Business News • PR NewsWire • Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress

Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress

Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress

VIENNA, Sept. 3, 2012 /PRNewswire/ -- Elevation Pharmaceuticals, Inc. today presented positive efficacy and safety results from the GOLDEN-1 study – a Phase 2b study evaluating EP-101 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) –...

View More : http://www.prnewswire.com/news-releases/elevation-pharmaceuticals-presents-positive-phase-2b-results-for-ep-101-in-copd-...

Releted News by prnewswire

Financial Services Directors Reveal how They are Using 'Big Data'

An Unconventional Reserves Future - Fivos Spathopolous Discusses How We Get There